

INCOME STATEMENT
Three months ended 31st March 2008

	Statutory Q1 2008	Statutory Q1 2007	Growth	
	£m	£m	CER%	£%
Turnover:				
Pharmaceuticals	4,793	4,806	(4)	-
Consumer Healthcare	893	786	8	14
TURNOVER	5,686	5,592	(3)	2
Cost of sales	(1,359)	(1,234)	6	10
Gross profit	4,327	4,358	(5)	(1)
Selling, general and administration	(1,745)	(1,673)	-	4
Research and development	(780)	(726)	(5)	7
Other operating income	161	207		
Operating profit:				
Pharmaceuticals	1,805	2,028		
Consumer Healthcare	158	138		
OPERATING PROFIT	1,963	2,166	(13)	(9)
Finance income	82	58		
Finance expense	(170)	(96)		
Share of after tax profits of associates and joint ventures	(1)	15		
PROFIT BEFORE TAXATION	1,874	2,143	(17)	(13)
Taxation	(542)	(610)		
<i>Tax rate %</i>	28.9%	28.5%		
PROFIT AFTER TAXATION FOR THE PERIOD	1,332	1,533	(17)	(13)
Profit attributable to minority interests	25	19		
Profit attributable to shareholders	1,307	1,514		
	1,332	1,533		
EARNINGS PER SHARE	24.4p	27.0p	(14)	(10)
Diluted earnings per share	24.2p	26.7p		

PHARMACEUTICAL TURNOVER
Three months ended 31st March 2008

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	1,355	6	11	616	8	6	495	4	15	244	5	16
<i>Seretide/Advair</i>	954	10	14	499	10	9	351	9	19	104	16	27
<i>Flixotide/Flovent</i>	162	(1)	5	75	7	6	45	(7)	7	42	(7)	-
<i>Serevent</i>	67	(5)	3	17	(11)	(11)	37	6	16	13	(21)	(7)
<i>Flixonase/Flonase</i>	46	(33)	(27)	4	(84)	(84)	14	-	8	28	-	12
<i>Veramyst</i>	13	-	-	12	-	-	1	-	-	-	-	-
CENTRAL NERVOUS	829	3	4	594	7	5	131	(7)	2	104	(8)	1
<i>Seroxat/Paxil</i>	121	(15)	(10)	31	(16)	(16)	29	(21)	(15)	61	(11)	(3)
<i>Paxil IR</i>	88	(13)	(5)	2	-	-	29	(21)	(15)	57	(12)	(3)
<i>Paxil CR</i>	33	(20)	(20)	29	(22)	(22)	-	-	-	4	-	-
<i>Wellbutrin</i>	126	(3)	(5)	121	(4)	(5)	3	>100	>100	2	(33)	(33)
<i>Wellbutrin IR, SR</i>	13	(43)	(43)	11	(45)	(45)	1	-	-	1	(50)	(50)
<i>Wellbutrin XL</i>	113	6	4	110	4	2	2	-	-	1	-	-
<i>Imigran/Imitrex</i>	165	(1)	(1)	134	-	(1)	23	(5)	10	8	(11)	(11)
<i>Lamictal</i>	290	16	16	240	22	20	34	(11)	(3)	16	-	7
<i>Requip</i>	94	15	18	60	9	7	29	24	38	5	67	67
ANTI-VIRALS	739	(8)	(4)	347	(9)	(10)	213	(15)	(6)	179	6	14
HIV	358	(5)	-	152	(6)	(7)	159	(6)	5	47	2	9
<i>Combivir</i>	105	(13)	(9)	45	(8)	(10)	43	(20)	(12)	17	(6)	6
<i>Trizivir</i>	54	(16)	(13)	27	(16)	(16)	24	(19)	(11)	3	-	-
<i>Epivir</i>	34	(22)	(17)	11	(21)	(21)	15	(22)	(17)	8	(22)	(11)
<i>Ziagen</i>	25	(8)	(4)	10	(9)	(9)	9	(11)	-	6	-	-
<i>Agenerase, Lexiva</i>	35	(3)	-	18	(10)	(10)	15	8	15	2	-	-
<i>Epzicom/Kivexa</i>	99	25	32	40	17	14	48	33	45	11	29	57
Herpes	274	6	10	174	7	5	45	11	25	55	2	15
<i>Valtrex</i>	249	9	11	173	7	5	37	18	32	39	9	22
<i>Zovirax</i>	25	(15)	(4)	1	(50)	(50)	8	(13)	-	16	(13)	-
<i>Zeffix</i>	46	8	15	3	-	-	7	-	17	36	10	16
<i>Relenza</i>	29	(71)	(68)	8	(82)	(82)	-	-	-	21	19	31
VACCINES	436	10	18	109	34	33	202	5	17	125	2	10
Hepatitis	139	16	23	53	66	66	57	(5)	2	29	-	16
Influenza	5	-	-	-	-	-	4	-	-	1	-	-
<i>Infanrix/Pediarix</i>	153	6	14	51	21	19	82	(1)	12	20	-	11
<i>Boostrix</i>	13	(8)	-	5	(29)	(29)	5	-	25	3	50	50
<i>Rotarix</i>	27	79	93	-	-	-	9	100	>100	18	70	80
<i>Cervarix</i>	12	-	-	-	-	-	10	-	-	2	-	-
CARDIOVASCULAR	398	(12)	(9)	232	(22)	(23)	119	6	19	47	19	31
<i>Coreg</i>	48	(77)	(78)	48	(78)	(78)	-	-	-	-	(50)	-
<i>Coreg CR</i>	35	>100	>100	35	>100	>100	-	-	-	-	-	-
<i>Coreg IR</i>	13	(94)	(94)	13	(94)	(94)	-	-	-	-	-	-
<i>Levitra</i>	14	-	-	13	-	-	1	-	-	-	-	-
<i>Avodart</i>	85	30	35	49	22	20	28	39	56	8	75	100
<i>Arixtra</i>	35	70	75	19	73	73	14	33	56	2	-	-
<i>Fraxiparine</i>	51	(4)	9	-	-	-	44	(7)	5	7	20	40
<i>Vesicare</i>	14	36	27	14	36	27	-	-	-	-	-	-
<i>Lovaza</i>	50	-	-	50	-	-	-	-	-	-	-	-
ANTI-BACTERIALS	365	(2)	5	45	(13)	(15)	181	(7)	3	139	10	16
<i>Augmentin</i>	156	(1)	6	17	(29)	(29)	82	-	12	57	10	14
<i>Altabax</i>	2	-	-	2	-	-	-	-	-	-	-	-
METABOLIC	274	(45)	(42)	133	(57)	(58)	74	(6)	4	67	(30)	(24)
<i>Avandia products</i>	191	(56)	(54)	99	(66)	(66)	54	(14)	(5)	38	(44)	(40)
<i>Avandia</i>	122	(62)	(61)	71	(69)	(69)	22	(35)	(29)	29	(48)	(44)
<i>Avandamet</i>	62	(29)	(25)	24	(49)	(49)	31	8	19	7	(30)	(30)
<i>Avandaryl</i>	7	(63)	(56)	4	(73)	(73)	1	-	-	2	-	100
<i>Bonviva/Boniva</i>	49	50	53	33	48	43	15	44	67	1	-	-
ONCOLOGY AND EMESIS	113	(27)	(23)	58	(41)	(42)	38	6	19	17	-	13
<i>Zofran</i>	29	(69)	(67)	3	(95)	(95)	16	(30)	(20)	10	(9)	(9)
<i>Hycamtin</i>	30	(3)	-	17	(5)	(11)	11	11	22	2	(50)	-
<i>Tykerb</i>	19	>100	>100	10	>100	>100	7	>100	>100	2	-	-
OTHER	284	13	18	4	(91)	(88)	73	20	30	207	32	36
	4,793	(4)	-	2,138	(10)	(12)	1,526	(1)	10	1,129	6	13

Pharmaceutical turnover includes co-promotion income.

CONSUMER HEALTHCARE TURNOVER
Three months ended 31st March 2008

	Q1 2008 £m	Growth	
		CER%	£%
Over-the-counter medicines	411	4	10
Analgesics	116	13	20
Dermatological	46	8	15
Gastrointestinal	68	-	3
Respiratory tract	71	18	27
Smoking control	58	(27)	(26)
Natural wellness support	32	-	7
Weight management	9	-	-
Oral care	289	8	17
Nutritional healthcare	193	14	18
Total	893	8	14